Health and disease are expensive for any government. Deciding which drugs and therapies to fund, which services to invest in, which to expand and develop, and which should be cut, is something that is not within our immediate control. Maternity care is viewed as essential, but the extra investment required to provide holistic and specialist care for those women with medical, psychiatric or social problems in pregnancy is not. Certainly in the UK the focus is on safe and senior staffing of the labour wards, and not on the development of services for women with medical problems in pregnancy.
cuts and squeezes to health services. Ensuring that less well-recognized areas of medicine such as medical disorders of pregnancy are supported is increasingly difficult, requiring political activism that is foreign to most clinicians. ' The rise and fall of a psychiatric antenatal clinic' by Shah and colleagues in this issue tells the story of one such specialist clinic and the difficulties it faced. The review articles in this quarter's issue of the journal deal with common medical problems encountered by us all. The field of oncology moves much faster than the field of obstetric medicine and women with newly diagnosed or previously treated breast cancer are seen with increasing frequency in pregnancy. It is important to keep up to date with the different histological classification, receptor status and likely interactions with pregnancy. Chemotherapy for breast cancer has surprisingly few adverse effects on pregnancy outcome. The review of breast cancer in pregnancy by Rita Sasidharan (based on her presentation at SOMANZ last year) and Harvey provides a useful review and update.
Similarly, the management of inflammatory bowel disease has advanced dramatically with the advent of biological therapy. The use of anti-TNF-alpha and other biological therapies in rheumatic disease were excellently reviewed by Yousseff and Kennedy in the December 2009 issue of the journal. 1 But these agents have also revolutionized the management of inflammatory bowel disease, particularly fistulizing Crohn's disease, and in this issue Smith and Sanderson review the management of inflammatory bowel disease in pregnancy.
We normally commission our review articles, but Yang and colleagues decided to send us their non-commissioned review of the literature of pregnancy outcomes in end-stage renal disease, or chronic kidney disease (CKD) stage 5 as we should now call it. Outcomes are much more encouraging than earlier literature suggested. Their review of the literature since 1995 found over 150 pregnancies in women on dialysis and the live birth rate was 75%, albeit at the expense of a 69% preterm delivery rate.
Of course, the best treatment for CKD 5 is transplantation and increasing numbers of women with end-stage renal failure due to diabetes are receiving simultaneous pancreaskidney allografts. Bramham and colleagues report on the outcome of pregnancies in three such women. Limb girdle muscular dystrophy is not something we encounter every day and as usual the case reports and case series make fascinating reading. They stimulate debate and highlight alternative approaches as demonstrated by the response of Drs Bhardwaj and Dixit to a previously published case report of hyponatraemia complicating preeclampsia.
Have you booked your flight to Melbourne yet? The fifth scientific meeting of ISOM in October 2010 takes us back where we started with the inaugural meeting in Australia in October 2003. The organizing committee have put together a fabulous programme and we urge you all to join us for what promises to be a very stimulating three days. Further details are available at http://www.isom2010.org.
